Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.83 | N/A | -31.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.83 | N/A | -31.47% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions but remains focused on their long-term strategy. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to advance their pipeline.
No specific updates on future milestones were provided.
Kodiak Sciences reported a larger-than-expected loss per share, which may raise concerns among investors about the company's financial health. Despite this, the stock rose by 2.83%, likely due to investor optimism about the company's long-term potential and ongoing projects. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
May 9, 2022